Pancreato-hepatobiliary neuroendocrine tumors diagnosed through endoscopic ultrasound: Clinical characteristics and factors associated with high-grade lesions

Table 4 Frequency of different pancreato-hepatobiliary regions affected by benign and malignant neuroendocrine tumors (n = 36)

PHB region affected		n (%)	Benign NET (n)	NEC (n)	Benign NET (%) (no/total)	NEC (%) (no/total)
Pancreas (n = 20)	Body	9 (45)	7	2	85%; (17/20)	15%; (3/20)
	Tail	5 (25)	5	0
	Head	5 (25)	4	1
	Neck	1 (5)	1	0
Extra-pancreatic PHB-NETs (n = 16)	Porta hepatis mass	8 (50)	2	6	43.7%; (7/16)	56.3%; (9/16)
	Peri-gastric mass	3 (18.7)	3	0
	Liver	1 (6.2)	0	1
	Ampulla	1 (6.2)	1	0
	Retroperitoneal mass	1 (6.2)	1	0
	Mediastinal LN1	2 (12.5)	0	2

¹Mediastinal lymphadenopathy (associated with malignant pancreato-hepatobiliary neuroendocrine cancer, not biopsiable through endoscopic ultrasound for technical reasons and proven later with percutaneous image guided biopsy).

PHB: Pancreato-hepatobiliary; LN: Lymph node; NEC: Neuroendocrine cancer; NET: Neuroendocrine tumor.